Skip to content

Clinical study on the effect of pretreatment with nalbuphine and ketorolac tromethamine on hyperalgesia after remifentanil anesthesia

Clinical study on the effect of pretreatment with nalbuphine and ketorolac tromethamine on hyperalgesia after remifentanil anesthesia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038836
Enrollment
Unknown
Registered
2020-10-05
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Remifentanil induced hyperalgesia

Interventions

Nalbuphine (Group T):The patient was injected with 0.2mg/kg nalbuphine hydrochloride (diluted to 5ml with normal saline) 15min before anesthesia induction, and then the tube was flushed with normal sa
ketorolac tromethamine (Group T):The patient was injected with 0.5mg/kg ketorolac tromethamine (diluted to 5ml by adding normal saline) 15min before anesthesia induction, and then the tube was flushed
nalbuphine+ketorolac tromethamine (GroupN+T):The patient was injected with 0.2mg/kg nalbuphine hydrochloride (diluted to 5ml by adding normal saline) 15min before anesthesia induction, and injected wi
placebo (Group A):The patient was injected with 5ml normal saline 15min before anesthesia induction, and 5ml normal saline was injected again after flushing the tube

Sponsors

The First Affiliated Hospital of Henan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Optional thoracoscopic lobectomy; (2) Patients aged 20 to 65 years; (3) ASA class I~ II; (4) BMI18 ~ 30kg/m2; (5) General anesthesia was agreed, and sufentanil - based PCIA was accepted; (6) Can communicate with the doctor normally, cooperate with preoperative, intraoperative, postoperative evaluation and testing; (7) No serious cardiovascular disease and normal liver and kidney function; (8) Patients or their family members sign the informed consent form for this study.

Exclusion criteria

Exclusion criteria: (1) Allergic to nabulphine, ketorolac tromethamine or other drugs in this study; (2) The patient did not take analgesic and sedative drugs recently; (3) There is a serious mental nervous system disease; (4) The patient has a complex internal systemic disease; (5) A pregnant or lactating woman; (6) People considered unsuitable by researchers for other reasons.

Design outcomes

Primary

MeasureTime frame
Mechanical pain threshold;

Secondary

MeasureTime frame
Intraoperative dosage of remifentanil;The number of times that PCA was effectively pressed within 24h after the patient was admitted to the ward;The time of the first effective pressure on PCA from the distance of extubation;Visual simulation scoring;Ramsay sedation score;

Countries

China

Contacts

Public ContactZheng Xiao-Zhen

The First Affiliated Hospital of Henan University

hedazxz@sina.com+86 13938632449

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026